Cerebrolysin: Neuropeptide     Purity: 98% (HPLC on request)CAS No.: 12656-61-0

MolecularStructure Description

Cerebrolysin (synonym FPE 1070) is a synthetic nootropic drug which consists of low-molecular peptides and possesses neuroprotective and neurotrophic repair properties. The active fragment of cerebrolysin is made of proteins which molecular masses do not exceed 10.000 daltons, so they can penetrate blood-brain (or blood-SCF) barrier and reach neurons directly which in turn makes the drug to be able to show organo-specific combined effects towards brain.

Cerebrolysin has been proven to have neurotrophic action similar to nerve growth factors causing peripheral and central neuronal stimulation. It improves efficiency within the brain’s aerobic metabolic processes and improves intracellular peptide synthesis. The neuroprotective properties of this nootropic agent help to shield neurons from lactocidosis, to prevent formation of free radicals and to decrease neurotoxic action of certain amino acids.

MicroscopeClinical Research

Cerebrolysin in Alzheimer’s disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

M. Panisset, S. Gauthier, H. Moessler, M. Windisch

Summary: Cerebrolysin (Cere) is a compound with neurotrophic activity. It has been shown to be effective in the treatment of Alzheimer’s disease (AD) in earlier trials. In this multicenter, randomized, double-blind, placebo-controlled, parallel-group study, patients were injected intravenously with placebo or 30 mL Cere five days per week for four weeks. Effects on cognition and global function were evaluated with the Alzheimer Disease Assessment Scale – Cognitive Subscale (ADAS-Cog) and the Clinicians Interview-based Impression of Change with Caregiver Input scale (CIBIC+) 4, 12, 24 weeks after the beginning of the injections. 192 patients were enrolled, 95 were randomized to placebo, and 97 to Cere. At baseline, there was a significant difference between groups for age, age of onset of dementia, and the number of patients with hallucinations. At week 12 there was a significant difference on the CIBIC+ (p = 0.033) in favor of Cere. The number of CIBIC+ responders (score ≤ 4), was significantly higher (p = 0.007), with 68 (76%) in the Cere group and 51 (57%) in the placebo group. Trends were noted in the Disability Assessment in Dementia scale and the Cornell Depression Scale. Adverse events were recorded in 73% of placebo and 64% of Cere patients. Most common adverse events were headaches, dizziness, weight loss and anxiety.

Conclusions: Cere treatment was well tolerated and resulted in significant improvements in the global score two months after the end of active treatment.

A full copy of all trials are available from Como Compounding Pharmacy. Please contact us for more information.

Download this information.